Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOLIPOP: 4-in-1 FDC in HIV Infected Children
NCT03836833Phase 2Unknown
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Jun 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of abacavir + lamivudine + lopinavir + ritonavir in human immunodeficiency virus infection (HIV), sponsored by Drugs for Neglected Diseases initiative. Status: unknown.
02
Drugs
abacavir + lamivudine + lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03836833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836833.